Hua Medicine (Shanghai) Ltd.
2552.HK
Price:
$3.08
Market Cap:
$2.74B
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorpora...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2018-09-14
Stock Exchange
HKSE
Ticker
2552.HK
PE Ratio
[2.57]
ROE
[232.98%]
Current Ratio
[7.79]
Dividend Yield
[0%]
Enterprise Value
[1.99B]
Dividend History
The ROE as of December 2025 (TTM) for Hua Medicine (Shanghai) Ltd. (2552.HK) is 232.98%
According to Hua Medicine (Shanghai) Ltd.’s latest financial reports and current stock price. The company's current ROE is 232.98%. This represents a change of 86.21% compared to the average of 125.12% of the last 4 quarters.
Hua Medicine (Shanghai) Ltd. (2552.HK) Historical ROE (quarterly & annually)
How has 2552.HK ROE performed in the past?
The mean historical ROE of Hua Medicine (Shanghai) Ltd. over the last ten years is -48.80%. The current 232.98% ROE has changed -577.42% with respect to the historical average. Over the past ten years (40 quarters), 2552.HK's ROE was at its highest in in the June 2024 quarter at 428.81%. The ROE was at its lowest in in the December 2018 quarter at -149.42%.
Average
-48.80%
Median
-54.12%
Minimum
-256.70%
Maximum
184.65%
Hua Medicine (Shanghai) Ltd. (2552.HK) ROE by Quarter and Year
Discovering the peaks and valleys of Hua Medicine (Shanghai) Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 186.53%
Maximum Annual ROE = 184.65%
Minimum Annual Increase = -997.86%
Minimum Annual ROE = -256.70%
| Year | ROE | Change |
|---|---|---|
| 2024 | 184.65% | -188.42% |
| 2023 | -208.83% | 186.53% |
| 2022 | -72.88% | -0.83% |
| 2021 | -73.49% | 35.79% |
| 2020 | -54.12% | 34.15% |
| 2019 | -40.34% | -84.28% |
| 2018 | -256.70% | -997.86% |
| 2017 | 28.59% | -46.98% |
Hua Medicine (Shanghai) Ltd. (2552.HK) Average ROE
How has 2552.HK ROE performed in the past?
The current ROE of Hua Medicine (Shanghai) Ltd. (2552.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32.35%
5-year avg
-44.93%
10-year avg
-48.80%
Hua Medicine (Shanghai) Ltd. (2552.HK) ROE vs. Peers
How is 2552.HK’s ROE compared to its peers?
Hua Medicine (Shanghai) Ltd.’s ROE is less than Clover Biopharmaceuticals, Ltd. (54.43%), less than OrbusNeich Medical Group Holdings Limited (10.14%), less than Jacobson Pharma Corporation Limited (12.32%), less than Saint Bella Inc. (0%), less than Golden Throat Holdings Group Company Limited (20.05%), less than Essex Bio-Technology Limited (14.24%), greater than VISEN Pharmaceuticals (-38.68%), less than Acotec Scientific Holdings Limited (7.22%), greater than Antengene Corporation Limited (-28.27%), greater than Jiangsu Recbio Technology Co., Ltd. (-184.99%),
| Company | ROE | Market cap |
|---|---|---|
| 54.43% | $3.13B | |
| 10.14% | $2.96B | |
| 12.32% | $2.49B | |
| 0% | $2.48B | |
| 20.05% | $2.31B | |
| 14.24% | $2.18B | |
| -38.68% | $4.15B | |
| 7.22% | $4.35B | |
| -28.27% | $2.47B | |
| -184.99% | $2.38B |
Build a custom stock screener for Hua Medicine (Shanghai) Ltd. (2552.HK) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Hua Medicine (Shanghai) Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Hua Medicine (Shanghai) Ltd. (2552.HK) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Hua Medicine (Shanghai) Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Hua Medicine (Shanghai) Ltd.'s ROE?
How is the ROE calculated for Hua Medicine (Shanghai) Ltd. (2552.HK)?
What is the highest ROE for Hua Medicine (Shanghai) Ltd. (2552.HK)?
What is the 3-year average ROE for Hua Medicine (Shanghai) Ltd. (2552.HK)?
What is the 5-year average ROE for Hua Medicine (Shanghai) Ltd. (2552.HK)?
How does the current ROE for Hua Medicine (Shanghai) Ltd. (2552.HK) compare to its historical average?